Table 4 The clinical background of 11 patients with AR-positive TNBC recurred
No | Age | Menopause | Tumour size (cm) | Lymph node status | Nuclear grade | Ki67 (%) | Pathological response | Disease-free interval (years) | AR expression of CNB specimens before NAC | AR expression of surgical specimens after NAC | AR expression of CNB specimens after recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 53 | Positive | 2.3 | Positive | 1 | 10 | Non-pCR | 0.85 | Positive | Positive | Positive |
2 | 40 | Negative | 3.2 | Negative | 3 | 75 | pCR | 0.76 | Positive | NA | Positive |
3 | 39 | Negative | 3.1 | Positive | 3 | 67 | Non-pCR | 0.99 | Positive | Positive | Negative |
4 | 30 | Negative | 3.3 | Negative | 2 | 50 | Non-pCR | 0.70 | Positive | Positive | Negative |
5 | 62 | Positive | 2.9 | Positive | 1 | 7 | Non-pCR | 0.10 | Positive | Positive | Negative |
6 | 65 | Positive | 2.5 | Positive | 3 | 71 | Non-pCR | 1.01 | Positive | Positive | NA |
7 | 58 | Positive | 2.2 | Positive | 2 | 57 | Non-pCR | 0.63 | Positive | Positive | NA |
8 | 44 | Negative | 1.8 | Positive | 2 | 82 | Non-pCR | 0.54 | Positive | Negative | Negative |
9 | 68 | Positive | 1.6 | Positive | 1 | 12 | Non-pCR | 0.88 | Positive | Negative | Negative |
10 | 63 | Positive | 3.8 | Positive | 3 | 62 | Non-pCR | 0.13 | Positive | Negative | Negative |
11 | 46 | Negative | 2.8 | Positive | 1 | 12 | pCR | 1.42 | Positive | NA | NA |
